EyeCRO Contributes to Evaluation of SPVN06 Gene Therapy
A new Gene Therapy publication details the safety and biodistribution assessment of SPVN06, a mutation-independent gene therapy in development for rod–cone dystrophies (RCDs). These inherited retinal disorders are a leading cause of vision loss and can result from mutations in more than 100 different genes, which makes developing broadly applicable treatments challenging.
SPVN06 is an adeno-associated virus (AAV) vector that delivers two complementary proteins, RdCVF and RdCVFL, to promote cone photoreceptor metabolism and protect against oxidative stress. By supporting cone survival and function, this approach has the potential to slow the progression of vision loss regardless of the genetic mutation responsible for disease.
EyeCRO contributed to the pharmacology and safety evaluation of SPVN06, applying its specialized ocular research capabilities to advance the therapy toward clinical development.
The study’s findings support the ongoing Phase I/II PRODYGY trial (NCT05748873) in patients with rod–cone dystrophy.